Lacutamab Clinical Trial for Certain CTCL Patients

Innate Pharma has recently announced phase 2 of a clinical trial dubbed TELLOMAK regarding the investigative drug lacutamab (IPH4102), an anti-KIR3DL2 monoclonal antibody, alone or in combination with chemo. The focus of this study is the treatment of patients with the rare cutaneous t-cell lymphoma (CTCL) Mycosis Fungoides and it’s systemic comparable Sézary Syndrome. The…… Continue reading Lacutamab Clinical Trial for Certain CTCL Patients